Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!
Apmv and uses thereof for treatment of cancer
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
一种APMV-4、癌症的技术，应用在优先权益领域
Pending Publication Date: 2021-04-30
MT SINAI SCHOOL OF MEDICINE
View PDF24 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Although the anti-tumor potential of NDV has been tested, no NDV-based anti-tumor therapy has been approved for cancer treatment
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment approach
[0506] The following exemplary implementations are provided herein:
[0507] 1. A method for the treatment of cancer, comprising administering to a human subject in need thereof a naturally occurring avian paramyxovirus serotype 4 (APMV-4), wherein the APMV-4 is present within 1 day of the Gallus gallus species - Intracerebral inoculation pathogenicity index less than 0.7 in large chicks.
[0508] 2. A method of treating cancer, comprising administering recombinant APMV-4 to a human subject in need thereof, wherein said recombinant APMV-4 is inoculated in the brain in 1 day-old chicks of Gallus gallus species The pathogenicity index was less than 0.7.
[0509] 3. The method of embodiment 1 or 2, wherein administration of APMV-4 reduces tumor growth and survival in a B16-F10 syngeneic murine melanoma model administered with phosphate buffered saline (PBS) demonstrated tumor growth and improved survival in a B16-F10 syngeneic murine melanoma model.
[0510] 4. The method of e...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
In one aspect, provided herein are naturally occurring and recombinantly produced avian paramyxovirus (APMV) (e.g., an APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9 strain) and uses of such APMV for the treatment of cancer. In particular, provided herein are methods for treating cancer comprising administering the naturally occurring or recombinantly produced APMV-4 strain to a subject in need thereof. In another aspect, provided herein are recombinant APMV comprising a packaged genome, wherein the packaged genome comprises a transgene. In particular, described herein are recombinant APMV (e g., APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9). In another aspect, provided herein are methods for treating cancer comprising administering a recombinant APMV (e g., APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV-9) to a subject in need thereof, wherein the recombinant APMV comprises a packaged genome comprising a transgene. In particular, provided herein are methods for treating cancer, comprising administering the recombinant APMV-4 to the subject in need thereof, wherein the recombinant APMV-4 comprises a packaged genome comprising a transgene. In specific aspects, the use of APMV serotypes other than APMV-1 (such as described herein, in particular AMPV-4) to treat cancer is based, in part, on the similar or enhanced in vivo anti-tumor activities when compared to oncolytic NDV La Sota-L289A strain.
Description
[0001] This application claims priority to US Provisional Patent Application No. 62 / 697,944, filed July 13, 2018, which is incorporated herein by reference in its entirety. [0002] The present application contains a Sequence Listing in ASCII format, filed electronically and incorporated herein by reference in its entirety. The ASCII copy created on July 9, 2019 is named 6923-282-888_SL.txt and is 322,198 bytes in size. [0003] 1 Introduction [0004] In one aspect, provided herein are naturally occurring and recombinantly produced avian paramyxoviruses (APMVs) (eg, APMV-2, APMV-3, APMV-4, APMV-6, APMV-7, APMV-8, and APMV- 9 strains) and the use of these APMVs for cancer therapy. Specifically, provided herein are methods of treating cancer comprising administering to a subject in need thereof a naturally occurring or recombinantly produced strain of APMV-4. In another aspect, provided herein is a recombinant APMV comprising a packaged genome, wherein the packaged genome comp...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More